Back to announcement
20250509_OMED_Laporan Informasi dan Fakta Material_31884764_lamp3.pdf
Other Text extracted OMEDSource file signed link, expires in 15 minutes
Extracted text 2
Page 1
OMED Achieves Double-Digit Growth in Q1 2025, Kicks Off the Year
by Boosting Exports to the U.S. Market
Surabaya, May 7, 2025 – PT Jayamas Medica Industri Tbk (IDX: OMED), a leading
integrated national medical device manufacturer, reported strong performance in the first
quarter of 2025. Amid global industry headwinds, OMED recorded revenue of IDR 436.3
billion, up from IDR 427.4 billion in the same period last year. Net profit grew 15.7% year-
on-year (YoY) to IDR 73.1 billion, with a margin of 16.8%. EBITDA also increased to IDR
98.4 billion, reflecting a healthy margin of 22.6%, driven by operational efficiency and
disciplined cost management.
This growth was also evident in the company’s operations. Sales volume rose 4.21% YoY
to 611.3 million units, supported by strong performance in the Biotech & Lab (+41.0%)
and Wound Care (+8.65%) segments. OMED also demonstrated strong pricing power,
with average selling prices increasing in the Hospital Furniture (+71.5%) and Walking Aids
& Rehab (+6.11%) segments, contributing to improved profitability.
On the product side, OMED maintained solid gross margins across key categories:
Disposable & Medical Consumables (32.9%), Wound Care (43.6%), and Antiseptic &
Dialysis Fluids (43.0%). This performance reflects OMED’s success in balancing
production cost efficiency with value-added product offerings tailored to domestic market
needs.
On the balance sheet, PT Jayamas Medica Industri Tbk (OMED) posted asset growth to
IDR 2.94 trillion as of the end of March 2025, up 3.9% from IDR 2.83 trillion at the end of
2024. Liabilities increased to IDR 368 billion, rising 11.5% from IDR 330 billion at year-
end 2024, yet remained within a conservative capital structure. The debt-to-equity ratio
(DER) stood low at 0.14x, reflecting a healthy risk profile and prudent financial
management. The interest-bearing debt ratio was also very low at just 0.06x,
underscoring the company’s minimal reliance on interest-bearing debt. OMED’s liabilities
were predominantly composed of trade payables, keeping funding structure efficient and
free from interest burden. Meanwhile, equity rose 2.8% to IDR 2.56 trillion from IDR 2.49
trillion at the end of the previous year, reflecting profit accumulation and a solid,
sustainable financial position.
Page 2
Looking ahead, OMED is entering a promising new phase of international expansion. The 245% U.S. import tariff hike on syringe products from China has opened strategic opportunities for alternative manufacturers, including those from Indonesia. In response to this global supply chain shift, OMED has begun receiving significant interest from prospective buyers in the U.S. market for its syringe products. This export potential strengthens OMED’s position as a key player in the global medical device supply chain and marks the beginning of a new export-driven growth chapter amid rising international demand for reliable and efficient Southeast Asian producers. “Our first- quarter performance reflects OMED’s strong fundamentals in navigating market challenges,” said Louis Hartanto, OMED’s Director of Sales & Marketing. “This achievement provides a solid foundation for accelerating the implementation of our strategic initiatives throughout 2025. With growing export market opportunities, we believe 2025 will be a pivotal year for delivering greater value to our shareholders and all stakeholders.” For more information, please contact: Hansen Teguh Investor Relations - PT Jayamas Medica Industri Tbk Email: corporate.secretary@onemed.co.id | ir@onemed.co.id Website: www.onemed.co.id
Names mentioned 1 people and organisations named in the text · linked when the evidence is strong
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.